Analysts' Actions: AMTD CLF GMCR MAR UAL

NEW YORK (TheStreet) -- CHANGE IN RATINGS:

AFLAC ( AFL) was downgraded at Sterne Agee to neutral from buy. Trading near 52-week highs despite negative EPS revision pressure, Sterne Agee said.

Altera ( ALTR) was downgraded at Lazard Capital Markets from buy to neutral. Company faces macro growth headwinds, Lazard Capital Markets said.

TD Ameritrade ( AMTD) was downgraded at Sterne Agee to neutral. $19 price target. Valuation call, as the stock is up 20% from its November lows, Sterne Agee said.

American Express ( AXP) was downgraded at J.P. Morgan from neutral to underweight. $60 price target. Company may struggle to regain its operating leverage, J.P. Morgan said.

B/E Aerospace ( BEAV) was downgraded at Deutsche from buy to hold. Valuation call, based on a $55 price target, Deutsche said.

Boston Scientific ( BSX) was upgraded at Credit Suisse from neutral to outperform. $7.50 price target. Sales visibility is improving, Credit Suisse said.

Celgene ( CELG) was upgraded at Bank of America/Merrill Lynch from neutral to buy. $115 price target. Company can deliver 25% compound annual earnings growth over the next five years, BofA/Merrill said.

Cliffs Natural ( CLF) was upgraded at Deutsche Bank from hold to buy. $48 price target. Sector is down, despite higher commodity prices, Deutsche said.

Duke Energy ( DUK) was upgraded at UBS to buy from neutral. $70 price target. Attractive risk/reward profile, UBS said.

Consolidated Edison ( ED) was downgraded at UBS to sell from neutral. $53 price target. New York politics leads to regulatory interference, UBS said.

FMC Technologies ( FTI) was upgraded at Morgan Stanley to overweight. $65 price target. Company is leveraged to better subsea processing and services demand, Morgan Stanley said.

Green Mountain ( GMCR) was upgraded at Argus from hold to buy. $50 price target. Company has strong brands and can benefit from higher coffee prices, Argus said.

Global Payments ( GPN) was initiated with a buy rating at UBS. $57 price target. Unique asset with difficult to replicate global footprint, UBS said.

Hyatt Hotels ( H) was initiated with an outperform rating at BMO Capital Markets. $45 price target. Strong growth potential, BMO said.

US Airways ( LCC) was downgraded at J.P. Morgan to neutral. See limited upside potential, even with an expected UAL merger, J.P. Morgan said.

Marriott International ( MAR) was initiated at BMO Capital Markets with a market perform rating. $41 price target. North America is not a bad place to be, BMO said.

Nektar Therapeutics ( NKTR) was initiated at Lazard Capital Markets with a buy rating. $15 price target. A bounty of attractive late stage programs, Lazard Capital Markets said.

Pharmacyclics ( PCYC) was initiated at Credit Suisse with an outperform rating. $79 price target. Most derisked pure play in oral lymphoma/leukemia drug class, Credit Suisse said.

Patterson ( PDCO) was downgraded at Goldman Sachs from neutral to sell. Company will likely be hurt by lower demand for high-tech dental equipment, Goldman said.

Petrologistics ( PDH) was upgraded at Citigroup to buy from neutral. $17 price target. Elevated propane to propylene spread seems sustainable given warm weather, Citigroup said.

PDL Biopharma ( PDLI) was downgraded at Credit Suisse from neutral to underperform. Valuation call, based on a $6 price target, Credit Suisse said.

Principal Financial Group ( PFG) was downgraded at Sterne Agee to neutral from buy. Valuation call, Sterne Agee said.

Regeneron Pharmaceuticals ( REGN) was downgraded at Jefferies downgraded to hold from buy. Limited upside on Eylea, Jefferies said.

Sirona Dental ( SIRO) was downgraded at Goldman Sachs from buy to neutral. Valuation call, based on a $67 price target, Goldman Sachs said.

Symantec ( SYMC) was upgraded at Morgan Stanley to overweight. $25 price target. Visibility is improving, and the company offers the best risk/reward in the industry, Morgan Stanley said.

United Continental ( UAL) was downgraded at J.P. Morgan to neutral. Valuation call, based on a $30 price target, J.P. Morgan said.

Vantiv ( VNTV) was initiated with a neutral rating at UBS. $22 price target. Attractive secular exposure, but fully valued shares, UBS said.

Vertex Pharmaceuticals ( VRTX) was downgraded at Lazard Capital Markets to neutral. Company is likely facing a transition year, Lazard Capital Markets said.

Watsco ( WSO) was downgraded at Robert Baird from outperform to neutral. Valuation call, based on a $77 price target, Robert Baird said.

STOCK COMMENTS / EPS CHANGES

Apple ( AAPL) estimates, target reduced at Nomura. Shares of AAPL now seen reaching $530. Estimates also cut, given lower expected iPhone sales. Neutral rating.

Caterpillar ( CAT) target raised at Credit Suisse to $124, according to Credit Suisse. Survey suggests that dealers are meeting sales forecasts. Outperform rating.

Dell ( DELL) target raised at Jefferies to $13, Jefferies said. LBO is a possibility. Hold rating.

Rock Tenn ( RKT) cut from Conviction Buy List at Goldman. Valuation call, based on an $83 price target.

St. Jude Medical ( STJ) numbers raised at Jefferies. Shares of STJ now seen reaching $39, Jefferies said. Estimates also raised on ending of near- term pressure from Riata/Durata. Hold rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs